AbbVie Inc., ABBV is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in USA, AbbVie Inc., ABBV has a market cap of 97833.41. Since its IPO date on the 1/2/2013, AbbVie Inc., ABBV performance year to date is 5.50%. Today AbbVie Inc., ABBV has gained -1.60%, with a current price of 60.17.
Ownership of the company is 0.10% for insider ownership while institutional ownership is 70.20%. The management of the company have seen the company have a payout ratio of 63.30%. Return of assets are at 10.00%, with return on investment at 16.90%.
In terms of debt levels and profit levels, AbbVie Inc., ABBV is seeing a long-term debt/equity of 6.62. While Total debt/equity is 6.71. With a profit margin of 23.10%, this is combined with a gross margin of 78.60%, and operating margin of 35.00%. AbbVie Inc. ability to meet debt levels, with a current ratio of 1.8, while the quick ratio is 1.6.
For the last year AbbVie Inc., ABBV has seen a EPS growth of 185.20%. A performance for the year of 11.32%. The 52-week high is -10.86%, and the 52-week low is 37.51%. The average volume for AbbVie Inc., ABBV is 5603388.
With a target price of 71.28, can AbbVie Inc., ABBV reach this target? Looking at the value indicators of AbbVie Inc., ABBV. AbbVie Inc. has a P/E of 17.25 and a forward P/E of 10.66. Perhaps the more useful indicator than P/E, is PEG which has a value of 1.06. AbbVie Inc. also has a P/S and a P/B of 3.95 and 17.34 respectively. For P/cash, AbbVie Inc. has a value of 12.23, while it is 23.87 for P/free cash flow.
At the current price of 60.17, AbbVie Inc. has a dividend yield of 3.79%. We see a return on equity of 119.80%.
Looking more long-term AbbVie Inc., is projected to get an EPS growth for the next five years of 16.25%. In the short-term an EPS growth of 17.40% in the next year is forecasted. This is after a EPS growth of 185.20% for this year and for the last five years a 3.50% growth has been seen.